Accent Microcell Ltd
ACCENTMICAccent Microcell Ltd's price has outrun its earnings. +86.0% in a year against EPS +32.7% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only 51% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (53 weeks in) while the P/E sits at the 79th percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +52.9% year on year, and 51% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Accent Microcell Ltd trades at ₹513, in a confirmed uptrend and 53 weeks into that stage. That is +33.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹244 to ₹513. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 40 straight weeks.
Today the stock is in a confirmed uptrend — week 53 of stage 2, confirmed. At ₹513 it trades +33.1% versus its 200-day average and sits at 100% of its 52-week range (₹244–₹513).
Against the market, two honest reads. Cumulative: over the last 2.6 years the stock moved +72% while the NIFTY 500 moved +24% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 40 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 79th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Accent Microcell Ltd trades at 27.1× P/E, at the pricey end of its own range (79th percentile). Its long-run median P/E is 20.9×, measured across 2.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 27.1× is at the pricey end of its own range (79th percentile), against a long-run median of 20.9× measured over 2.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +32.7% against a +86.0% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Accent Microcell Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +31.7% | +21.0% | +21.3% | — |
| Profit | +33.3% | +54.2% | +54.5% | — |
| EPS | +32.7% | +30.3% | +13.3% | — |
| Share price | +86.0% | — | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
58.9/100 — rank 10 of 43 in Pharma - Formulators · 63% evidence confidence
Accent Microcell Ltd scores 58.9 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 10. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.5 + 18.1 + 9.6 + 13.7 = 58.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Accent Microcell Ltd reported ₹210 Cr of revenue in the Mar 26 quarter, +51.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 7 years it has compounded at 17.3% a year. The last full year, FY26, came in at ₹349 Cr. The last four reported quarters add to ₹614 Cr.
Accent Microcell Ltd reported ₹210 Cr of revenue in the Mar 26 quarter, +51.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 7 years it has compounded at 17.3% a year. The last full year, FY26, came in at ₹349 Cr. The last four reported quarters add to ₹614 Cr.
FY26 revenue came in at ₹349 Cr (+31.7% on the year), capping 7 years at 17.3% compound. The latest quarter (Mar 26) printed ₹210 Cr, +51.1% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +19.8% growth against the decade's 17.3% — the current year is running faster than its own long-run rate.
→ Revenue grew — did margins hold as it scaled? Next: 16.0% this quarter (−1.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Accent Microcell Ltd's operating margin is 16.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +2.0 percentage points. Across 8 fiscal years the operating margin has ranged 5.0% to 16.0%.
Accent Microcell Ltd's operating margin is 16.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +2.0 percentage points. Across 8 fiscal years the operating margin has ranged 5.0% to 16.0%.
The latest quarter's operating margin is 16.0%, −1.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 5.0%–16.0%, and FY26's 16.0% is the top of that band — a record year.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went +0.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins slipped — did that reach the bottom line? Next: profit +52.9% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Accent Microcell Ltd earned ₹26.0 Cr of net profit in the Mar 26 quarter, +52.9% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹44.0 Cr. The 7-year compound rate is 40.9%. That is 12.4% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.
Accent Microcell Ltd earned ₹26.0 Cr of net profit in the Mar 26 quarter, +52.9% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹44.0 Cr. The 7-year compound rate is 40.9%. That is 12.4% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.
Mar 26 profit was ₹26.0 Cr, +52.9% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹44.0 Cr (+33.3%), and the 7-year compound rate is 40.9%.
Why profit moved: revenue contributed +51.1% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +21.5% vs revenue +19.8%. Profit and revenue are moving roughly in step.
→ Profit rose — but did the cash follow? Next: 51% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 51% of Accent Microcell Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹19.0 Cr of operating cash against ₹44.0 Cr of profit. After ₹99.0 Cr of capital spending, ₹−80.0 Cr was left as free cash.
FY26: operating cash of ₹19.0 Cr against reported profit of ₹44.0 Cr, leaving free cash of ₹−80.0 Cr after ₹99.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 51% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 51%: the cash cycle stretched 29 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 29 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 117-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Accent Microcell Ltd's cash conversion cycle runs 117 days in FY26, up from 88 days in FY21. Capital spending ran ₹137 Cr over the last 3 years. At FY26 sales of ₹349 Cr each day of that cycle holds about ₹1.0 Cr, so roughly ₹112 Cr sits inside the business at any moment.
FY26: debtors at 95 days, inventory at 55 days — roughly 1.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 117 days, looser than FY21's 88.
The full loop: cash goes out to suppliers and production on day 0; stock waits 55 days to sell; customers pay about 95 days after that; and suppliers themselves are paid at 33 days — netting out to the 117-day cycle.
In money terms: at FY26 sales of ₹349 Cr, each day of the cycle holds about ₹1.0 Cr — so the 117-day loop keeps roughly ₹112 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹137 Cr over the last 3 fiscal years against ₹13.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹102 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 25% and the ROIC − WACC spread is +5.3 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Accent Microcell Ltd earns a ROCE of 25% in FY26. That is up from a trough of 17% in FY21. Return on invested capital clears the cost of that capital by +5.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.6% net margin on 1.08× asset turns.
FY26 ROCE is 25%, recovered from a FY21 trough of 17% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.6% net margin × 1.08× asset turns × 1.17× balance-sheet leverage ≈ 15.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 17.3% − 12.0% = a +5.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Accent Microcell Ltd carries total debt of ₹1.0 Cr against shareholder equity of ₹275 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.08 in FY24 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹1.0 Cr against shareholder equity of ₹275 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.08 (FY24) to 0.00 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 2.1 points over 7 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 2.1 points of Accent Microcell Ltd over 7 quarters, the biggest move on the register. That takes promoters to 53.0% of the company. Domestic institutions moved +1.9 points over the same window, to 3.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −2.1 points over 7 quarters to 53.0%; Domestic institutions: +1.9 points over 7 quarters to 3.5%; Foreign institutions: +0.9 points over 7 quarters to 0.9%.
🚨 Why the register moved: promoters drove it (−2.1 points), absorbed on the other side by domestic institutions (+1.9 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Accent Microcell Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Accent Microcell Ltd this page | 27.1× | ₹1,187 Cr | No read | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Accent Microcell Ltd's share price today?
Accent Microcell Ltd trades at ₹513, +86.0% over the past year. The company is valued at ₹1,187 Cr. The stock sits at 100% of its 52-week range of ₹244–₹513, +33.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 53 weeks in. — as of 24 July 2026.
What were Accent Microcell Ltd's latest quarterly results?
Accent Microcell Ltd reported revenue of ₹210 Cr and net profit of ₹26.0 Cr for the Mar 26 quarter. Revenue rose 51.1% and profit rose 52.9% year on year. Earnings per share were ₹10.75. The operating margin was 16.0%, 1.0 pp lower than a year earlier. — as of 24 July 2026.
What is Accent Microcell Ltd's revenue?
Accent Microcell Ltd reported revenue of ₹210 Cr in the Mar 26 quarter, +51.1% year on year. For the full FY26 fiscal year, revenue was ₹349 Cr (+31.7%). Over the last 7 years revenue compounded at 17.3% a year. — as of 24 July 2026.
What is Accent Microcell Ltd's profit?
Accent Microcell Ltd earned ₹26.0 Cr of net profit in the Mar 26 quarter, +52.9% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹44.0 Cr. The operating margin ran 16.0% in the latest quarter. — as of 24 July 2026.
What is Accent Microcell Ltd's market cap?
Accent Microcell Ltd's market capitalisation is ₹1,187 Cr at a share price of ₹513. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Accent Microcell Ltd's P/E ratio?
Accent Microcell Ltd trades at a P/E of 27.1×, at the 79th percentile of its own 3-year range, against a long-run median of 20.9×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Accent Microcell Ltd pay a dividend?
Yes — Accent Microcell Ltd's dividend payout was 5% of profit in FY26, and it recorded a payout in 6 of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Accent Microcell Ltd overvalued?
On its own history, Accent Microcell Ltd looks expensive against its own history: its P/E of 27.1× sits at the 79th percentile of its 3-year range (long-run median 20.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Accent Microcell Ltd growing?
Yes — Accent Microcell Ltd is growing: latest-quarter revenue +51.1% year on year, profit +52.9%, and the margin −1.0 pp at 16.0%. The 7-year compound rates are 17.3% (revenue) and 40.9% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Accent Microcell Ltd performing?
Accent Microcell Ltd is in a confirmed uptrend, 53 weeks in. Its latest quarter's revenue rose 51.1% and profit rose 52.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 40 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Accent Microcell Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 53 of stage 2), trading +33.1% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Accent Microcell Ltd beating the market?
On recent form, yes — Accent Microcell Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 40 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.6 years the stock moved +72% against the NIFTY 500's +24% — ahead of the index over the full window. — as of 24 July 2026.
Will Accent Microcell Ltd's share price go up?
This page publishes no price forecast for Accent Microcell Ltd. What it measures instead: the share price is ₹513, the price is in a confirmed uptrend 53 weeks in. Its P/E of 27.1× sits at the 79th percentile of its own 3-year range. — as of 24 July 2026.
Who owns Accent Microcell Ltd?
Promoters hold 53.0% of Accent Microcell Ltd, foreign institutions 0.9%, domestic institutions 3.5% and the public 42.5% (latest quarter). The biggest move on the register over the last two years: Promoters cut 2.1 points over 7 quarters. — as of 24 July 2026.
Does Accent Microcell Ltd have too much debt?
No — Accent Microcell Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 57×. FY26 borrowings were ₹1.0 Cr against equity of ₹276 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Accent Microcell Ltd's capex?
Accent Microcell Ltd spent ₹137 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹99.0 Cr, with ₹102 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Accent Microcell Ltd's cash flow?
Accent Microcell Ltd generated ₹19.0 Cr of operating cash flow in FY26 and ₹−80.0 Cr of free cash flow after ₹99.0 Cr of capital spending. Reported profit that year was ₹44.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Accent Microcell Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 51% of Accent Microcell Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹19.0 Cr against reported profit of ₹44.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
Where is Accent Microcell Ltd in its business cycle?
Accent Microcell Ltd's FY26 operating margin was 16.0%, against a 8-year band of 5.0%–16.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Accent Microcell Ltd story?
The sharpest disagreement: profits are rising, but only 51% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Accent Microcell Ltd a stock worth studying right now?
This is not investment advice. The machine read: Accent Microcell Ltd's price has outrun its earnings. +86.0% in a year against EPS +32.7% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.